A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
BUSINESS
ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
ASKA Pharmaceutical said on June 25 that it will start a PIII clinical trial in Japan of AKP-022, a relugolix combination therapy licensed from Takeda Pharmaceutical, for the treatment of endometriosis. Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist discovered…
To read the full story
Related Article
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
June 3, 2024
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- ASKA Earns Japan Rights to Takeda’s Relugolix Combo Drug
September 28, 2021
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
BUSINESS
- Chugai Sees 20% of Workforce Apply for Internal Job Postings
July 29, 2025
- Stella to Seek Japan Approval for BNCT as Angiosarcoma Trial Hits Goal
July 29, 2025
- Deciphera’s TGCT Drug Gets Key EMA Backing: Ono
July 29, 2025
- Opdivo-Yervoy Combo Approved for 1st Line HCC in Taiwan
July 29, 2025
- Shionogi, Torii to Start Co-Promotion in September upon Takeover
July 29, 2025
In the race to develop next-generation antibody therapies for solid tumors, antibody drug conjugates (ADCs) are surging, while T-cell engagers…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…